Ovarian cancer drug trial halted early: what happened?

NCT ID NCT06964165

Terminated Disease control Sponsor: Tesaro, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to see if the drug niraparib works better than standard chemotherapy before surgery for people with a specific type of advanced ovarian cancer (stage III or IV with HRd). The trial was planned for 36 participants but was stopped early. Researchers wanted to measure how many tumors shrank or disappeared with each treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HOMOLOGOUS RECOMBINATION-DEFICIENT STAGE III/IV OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian carcinoma ovarian neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN NEOPLASMS

Contacts and locations

Locations

GSK Investigational Site

San Francisco, California, 94115, United States
GSK Investigational Site

Miami, Florida, 33136, United States
GSK Investigational Site

Tampa, Florida, 33606, United States
GSK Investigational Site

Scarborough, Maine, 04074, United States
GSK Investigational Site

Boston, Massachusetts, 02114, United States
GSK Investigational Site

St Louis, Missouri, 63141, United States
GSK Investigational Site

New York, New York, 10029, United States
GSK Investigational Site

New York, New York, 77030, United States
GSK Investigational Site

Rochester, New York, 14642, United States
GSK Investigational Site

Sioux Falls, South Dakota, 57105, United States
GSK Investigational Site

Seattle, Washington, 98104, United States
GSK Investigational Site

Ottawa, Ontario, K1H 8L6, Canada
GSK Investigational Site

Montreal, Quebec, H2X 0A9, Canada
GSK Investigational Site

Montreal, Quebec, H4A 3J1, Canada
GSK Investigational Site

A Coruña, ES, 15006, Spain
GSK Investigational Site

Madrid, ES, 28027, Spain
GSK Investigational Site

Madrid, ES, 28033, Spain
GSK Investigational Site

Madrid, ES, 28050, Spain
GSK Investigational Site

Madrid, ES, 28223, Spain
GSK Investigational Site

Málaga, ES, 29001, Spain
GSK Investigational Site

Pamplona, ES, 31008, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.